Commerce Secretary Sunil Barthwal held high-level discussions in Switzerland on May 10, 2026, to expedite the rollout of the India-EFTA Trade and Economic Partnership Agreement (TEPA), signed last year between India and the European Free Trade Association (EFTA) bloc—comprising Switzerland, Norway, Iceland, and Liechtenstein.
From a medical healthcare standpoint, these talks signal accelerated access to advanced European medical technologies for India’s hospitals and diagnostics labs. The pact promises duty-free imports of up to $100,000 crore worth of EFTA goods over 15 years, including high-end imaging equipment, precision diagnostics tools, and surgical devices from Swiss giants like Roche and Straumann. This influx could address critical shortages in India’s healthcare infrastructure, enabling faster upgrades for public and private facilities amid rising demand for AI-driven diagnostics and minimally invasive procedures.
For India’s burgeoning medical device manufacturing ecosystem—bolstered by the PLI scheme—the agreement opens investment commitments of $100,000 crore from EFTA nations, fostering tech transfers and joint ventures. Local players in Delhi-NCR and other hubs stand to gain from European expertise in biotech and medtech, potentially slashing import dependency from 80-85% while creating jobs in high-skill areas like laboratory automation and digital health solutions.
Stakeholders in the healthcare sector, including lab chains and hospital networks, view the accelerated rollout as timely, aligning with India’s push for self-reliance under Ayushman Bharat Digital Mission. Final hurdles on tariff concessions and investment safeguards are expected to be cleared soon, paving the way for TEPA’s operationalization by Q3 2026.
MB Bureau